NYSE - Delayed Quote • USD
Boston Scientific Corporation (BSX)
At close: April 25 at 4:00 PM EDT
After hours: April 25 at 7:59 PM EDT
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Total Revenue
14,240,000.00
14,240,000.00
12,682,000.00
11,888,000.00
9,913,000.00
Cost of Revenue
4,345,000.00
4,345,000.00
3,956,000.00
3,711,000.00
3,510,000.00
Gross Profit
9,895,000.00
9,895,000.00
8,726,000.00
8,177,000.00
6,403,000.00
Operating Expense
7,478,000.00
7,478,000.00
6,693,000.00
6,353,000.00
5,719,000.00
Operating Income
2,417,000.00
2,417,000.00
2,033,000.00
1,824,000.00
684,000.00
Net Non Operating Interest Income Expense
-243,000.00
-243,000.00
-460,000.00
-337,000.00
-358,000.00
Other Income Expense
-188,000.00
-188,000.00
-434,000.00
-412,000.00
-405,000.00
Pretax Income
1,985,000.00
1,985,000.00
1,141,000.00
1,076,000.00
-79,000.00
Tax Provision
393,000.00
393,000.00
443,000.00
36,000.00
2,000.00
Net Income Common Stockholders
1,570,000.00
1,570,000.00
642,000.00
985,000.00
-115,000.00
Diluted NI Available to Com Stockholders
1,570,000.00
1,570,000.00
642,000.00
985,000.00
-115,000.00
Basic EPS
1.08
1.08
0.45
0.69
-0.08
Diluted EPS
1.07
1.07
0.45
0.69
-0.08
Basic Average Shares
1,453,000.00
1,453,000.00
1,430,500.00
1,422,300.00
1,416,700.00
Diluted Average Shares
1,463,500.00
1,463,500.00
1,439,700.00
1,433,800.00
1,416,700.00
Total Operating Income as Reported
2,343,000.00
2,343,000.00
1,649,000.00
1,199,000.00
-80,000.00
Total Expenses
11,823,000.00
11,823,000.00
10,649,000.00
10,064,000.00
9,229,000.00
Net Income from Continuing & Discontinued Operation
1,593,000.00
1,593,000.00
698,000.00
1,041,000.00
-82,000.00
Normalized Income
1,732,548.00
1,732,548.00
953,398.00
1,430,516.73
218,760.00
Interest Income
22,000.00
22,000.00
10,000.00
4,000.00
3,000.00
Interest Expense
265,000.00
265,000.00
470,000.00
341,000.00
361,000.00
Net Interest Income
-243,000.00
-243,000.00
-460,000.00
-337,000.00
-358,000.00
EBIT
2,250,000.00
2,250,000.00
1,611,000.00
1,417,000.00
282,000.00
EBITDA
3,446,000.00
3,446,000.00
2,747,000.00
2,510,000.00
1,405,000.00
Reconciled Cost of Revenue
3,977,000.00
3,977,000.00
3,623,000.00
3,359,000.00
3,176,000.00
Reconciled Depreciation
1,196,000.00
1,196,000.00
1,136,000.00
1,093,000.00
1,123,000.00
Net Income from Continuing Operation Net Minority Interest
1,593,000.00
1,593,000.00
698,000.00
1,041,000.00
-82,000.00
Total Unusual Items Excluding Goodwill
-174,000.00
-174,000.00
-418,000.00
-403,000.00
-412,000.00
Total Unusual Items
-174,000.00
-174,000.00
-418,000.00
-403,000.00
-412,000.00
Normalized EBITDA
3,620,000.00
3,620,000.00
3,165,000.00
2,913,000.00
1,817,000.00
Tax Rate for Calcs
0.00
0.00
0.00
0.00
0.00
Tax Effect of Unusual Items
-34,452.00
-34,452.00
-162,602.00
-13,483.27
-111,240.00
12/31/2020 - 5/19/1992
Upgrade to begin using 40 years of financial statements and get so much more.
Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.
UpgradeRelated Tickers
ALGN Align Technology, Inc.
310.50
-1.05%
MDT Medtronic plc
79.25
-1.41%
ABT Abbott Laboratories
106.86
-0.03%
SYK Stryker Corporation
337.15
+0.09%
EW Edwards Lifesciences Corporation
88.01
-0.68%
DXCM DexCom, Inc.
138.01
+0.10%
SWAV Shockwave Medical, Inc.
328.99
+0.04%
INSP Inspire Medical Systems, Inc.
231.01
-1.36%
TMDX TransMedics Group, Inc.
89.25
+0.42%
BIO Bio-Rad Laboratories, Inc.
275.60
-0.94%